Fig. 2From: CDH22 hypermethylation is an independent prognostic biomarker in breast cancerMolecular status of CDH22 in BC. a Methylation in three CpG sites was examined by pyrosequencing in a series of 142 BC cases, along with matched adjacent-to-tumour tissues (n = 26), and non-neoplastic mammary tissues from reduction mammoplasties (n = 19). The horizontal line in each group represents the median of the series (*p < 0.001). b Contingency table showing association between CDH22 immunohistochemical expression and the CpG site methylation status in our series of BC patients (*p = 0.01). c CDH22 expression was restored by epigenetic drugs in six BC cell lines and the immortalised but non-neoplastic mammary cell line HBL-100, as measured by qRT-PCR. 293T cells were used as a positive controlBack to article page